SAARBRÜCKEN, Germany & HEIDELBERG, Germany–(BUSINESS WIRE)–URSAPHARM and Novaliq jointly announce its partnership agreement as well as the initial European launch of EvoTears for the treatment of evaporative dry eye diseases.
Riassunto: URSAPHARM GmbH e Novaliq GmbH annunciano un accordo di collaborazione in Europa
SAARBRÜCKEN e HEIDELBERG, Germania–(BUSINESS WIRE)–URSAPHARM, una delle società europee leader nel settore dell’oftalmologia, e Novaliq, casa farmaceutica specializzata nella ricerca clinica con una piattaforma tecnologica innovativa per il rilascio dei farmaci oftalmici, hanno oggi annunciato la sigla di un contratto di collaborazione e il lancio di EvoTears™ sul mercato europeo. Come parte dell’accordo, URSAPHARM ottiene la licenza esclusiva per la commercializzazione di EvoTears, il primo
URSAPHARM GmbH und Novaliq GmbH melden europäische Partnerschaftsvereinbarung
SAARBRÜCKEN und HEIDELBERG–(BUSINESS WIRE)–URSAPHARM, eines der führenden europäischen Unternehmen auf dem Gebiet der Augenheilkunde, und Novaliq, ein Unternehmen für pharmazeutische Spezialprodukte in der klinischen Entwicklung mit einer innovativen Drug-Delivery-Plattform mit Schwerpunkt in der Augenheilkunde, meldeten heute gemeinsam die Unterzeichnung der Partnerschaftsvereinbarung sowie den ersten Marktauftritt von EvoTears™ in Europa. Im Rahmen der Vereinbarung erhält URSAPHARM die exkl
WHO Calls for Major Shift in View Toward Older People
The WHO’s ‘World Report on Aging and Health’ advises thinking about expenditures for older adults as ‘investments’ rather than ‘costs’ and calls for a re-examination of outdated stereotypes. Medscape Medical News
Acacia Subsidiary Enters into Settlement and Patent License Agreement with Alcatel Lucent USA Inc.
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Acacia Research Corporation (NASDAQ: ACTG) announced today that its Labyrinth Optical Technologies LLC subsidiary has entered into a settlement and patent license agreement with Alcatel Lucent USA Inc. The agreem…
Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients
The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.